dc.contributor.author |
Dissanayake, Ajith |
|
dc.contributor.author |
Vandal, Alain C |
|
dc.contributor.author |
Boyle, Veronica |
|
dc.contributor.author |
Park, Diane |
|
dc.contributor.author |
Milne, Bobbie |
|
dc.contributor.author |
Grech, Roger |
|
dc.contributor.author |
Ng, Anthony |
|
dc.coverage.spatial |
England |
|
dc.date.accessioned |
2022-07-12T03:22:42Z |
|
dc.date.available |
2022-07-12T03:22:42Z |
|
dc.date.issued |
2020-01-20 |
|
dc.identifier.citation |
(2020). BMJ Open, 10(1), e029009-. |
|
dc.identifier.issn |
2044-6055 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/60360 |
|
dc.description.abstract |
<h4>Introduction</h4>One in four diabetes patients will develop a foot ulcer over their lifetime. The role of glycaemic control in the healing of foot ulcers in diabetes patients is not supported by randomised controlled trial (RCT) data.<h4>Objectives</h4>To determine the feasibility of an RCT of glycaemic control with intensive insulin therapy in diabetic foot ulcer, by assessing: entry criteria, fasting capillary blood glucose (FCBG) medication satisfaction and sensitivity of different ulcer-healing endpoints to glycaemic control.<h4>Design</h4>Two substudies: one cross-sectional and one single-arm prospective.<h4>Setting</h4>Single-centre secondary care diabetic foot clinic in New Zealand.<h4>Participants</h4>Substudy 1: 78 participants consisting of all people ≥18 years with a diabetic foot ulcer presenting to the clinic over 35 weeks in 2015.Substudy 2: 15 participants from Substudy 1 consenting to intensive insulin therapy.<h4>Intervention</h4>Substudy 1: None.Substudy 2: Intensive insulin therapy with standard podiatry care over 24 weeks.<h4>Outcome</h4>Substudy 1: Proportion of participants satisfying potential RCT entry criteria; medication satisfaction (Diabetes Medication Satisfaction).Substudy 2: FCBG, index ulcer healing time, index ulcer size, health-related quality of life (HRQoL; EuroQol 5 Dimensions 5 Levels and Diabetic Foot Ulcer Scale-Short Form).<h4>Results</h4>Proportion in Substudy 1 satisfying all entry criteria was 31% (95% CI 21 to 42). FCBG values decreased between baseline and study end (difference -3.7 mmol/L, 95% CI -6.5 to -0.8); 83% (95% CI 44 to 95) of ulcers healed by 24 weeks. FCBG correlated negatively with medication satisfaction. Ulcer area logarithm was most sensitive to FCBG changes, displaying significant negative correlation with HRQoL outcomes. Detecting a 30% between-group difference in this outcome (80% power, α=5%) requires 220 participants per arm, achievable within 1 year with 15 centres similar to study setting.<h4>Conclusions</h4>An adequately powered RCT requires cooperation between a large number of centres. Ulcer area logarithm should be primary endpoint.<h4>Trial registration number</h4>ANZCTR ACTRN12617001414303. |
|
dc.format.medium |
Electronic |
|
dc.language |
eng |
|
dc.publisher |
BMJ |
|
dc.relation.ispartofseries |
BMJ open |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc/4.0/ |
|
dc.subject |
Humans |
|
dc.subject |
Diabetic Foot |
|
dc.subject |
Insulin |
|
dc.subject |
Blood Glucose |
|
dc.subject |
Hypoglycemic Agents |
|
dc.subject |
Endpoint Determination |
|
dc.subject |
Cross-Sectional Studies |
|
dc.subject |
Feasibility Studies |
|
dc.subject |
Podiatry |
|
dc.subject |
Wound Healing |
|
dc.subject |
Quality of Life |
|
dc.subject |
Adult |
|
dc.subject |
Aged |
|
dc.subject |
Aged, 80 and over |
|
dc.subject |
Middle Aged |
|
dc.subject |
Patient Satisfaction |
|
dc.subject |
New Zealand |
|
dc.subject |
Female |
|
dc.subject |
Male |
|
dc.subject |
Glycated Hemoglobin A |
|
dc.subject |
Glycemic Control |
|
dc.subject |
statistics & research methods |
|
dc.subject |
wound management |
|
dc.subject |
Clinical Research |
|
dc.subject |
Diabetes |
|
dc.subject |
Clinical Trials and Supportive Activities |
|
dc.subject |
Skin |
|
dc.subject |
Metabolic and endocrine |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Medicine, General & Internal |
|
dc.subject |
General & Internal Medicine |
|
dc.subject |
INSULIN-TREATMENT |
|
dc.subject |
SATISFACTION |
|
dc.subject |
VALIDATION |
|
dc.subject |
MANAGEMENT |
|
dc.subject |
RISK |
|
dc.subject |
1103 Clinical Sciences |
|
dc.subject |
Clinical |
|
dc.subject |
Clinical Medicine and Science |
|
dc.subject |
Nutrition |
|
dc.subject |
1117 Public Health and Health Services |
|
dc.subject |
1199 Other Medical and Health Sciences |
|
dc.title |
Does intensive glycaemic control promote healing in diabetic foot ulcers? - a feasibility study. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1136/bmjopen-2019-029009 |
|
pubs.issue |
1 |
|
pubs.begin-page |
e029009 |
|
pubs.volume |
10 |
|
dc.date.updated |
2022-06-07T01:39:51Z |
|
dc.rights.holder |
Copyright: The author |
en |
dc.identifier.pmid |
31964660 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/31964660 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
|
pubs.subtype |
research-article |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
793300 |
|
pubs.org-id |
Science |
|
pubs.org-id |
Statistics |
|
dc.identifier.eissn |
2044-6055 |
|
dc.identifier.pii |
bmjopen-2019-029009 |
|
pubs.number |
ARTN e029009 |
|
pubs.record-created-at-source-date |
2022-06-07 |
|
pubs.online-publication-date |
2020-01 |
|